| Old Articles: <Older 7801-7810 Newer> |
|---|
 |
The Motley Fool
August 13, 2011
Frank Vinluan |
Investors Blocking Pfizer's Bid Say Icagen's Value Could Be $165 Million Pfizer is offering a third of that figure for the pharma.   |
The Motley Fool
August 12, 2011
David Williamson |
Does "FDA" Stand for "Faster Drug Approvals"? FDA approvals for 2011 just surpassed 2010. |
The Motley Fool
August 12, 2011
David Williamson |
What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter? |
The Motley Fool
August 12, 2011
Evan Niu |
One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval. |
The Motley Fool
August 12, 2011
Rex Moore |
Could Amgen Be Hiding Weakness? Here are Amgen's numbers, as well as a bonus look at a few other companies in the same industry. |
The Motley Fool
August 12, 2011
Selena Maranjian |
Make Money in Health-Care Companies the Easy Way There's no need to guess which health-care company will perform best. A well-chosen ETF can grant you instant diversification across the industry -- and make investing in and profiting from its companies that much easier. |
The Motley Fool
August 11, 2011
Sean Williams |
Aeterna Zentaris: Out of Sight, Out of Mind Perifosine, the company's lead cancer drug, hits key milestones. |
Chemistry World
August 11, 2011
Simon Hadlington |
Getting to the Core of a Tumour for Drug Study Researchers have devised new a way to test how well drugs penetrate the low-oxygen core of solid tumors. |
The Motley Fool
August 11, 2011
Brian Orelli |
Amarin Gets 1 Step Closer to the Big Time Amarin can start its outcomes study. The company announced yesterday that it had reached an agreement with the Food and Drug Administration to run an outcomes study for its fish oil drug, AMR101. |
The Motley Fool
August 11, 2011
Brian Orelli |
Dendreon's a Broken IPO, Again $10 isn't really a magical number. |
| <Older 7801-7810 Newer> Return to current articles. |
